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1. Introduction
1.1. Aging and inflammaging
Aging can be defined as the accumulation of unrepaired, deleterious changes occurring in the
molecules, cells, tissues and organs of the body over time generated by internal and external
sources. An integral part of the aging process is represented by the adaptive mechanisms that
the body sets up to compensate and neutralize the adverse effects of such damage that lead to
a progressive change of the body composition and its microenvironments. Among others, the
multifaceted dynamic process, known as immunosenescence, encompasses all the complex
changes occurring in the immune system during aging. It results from the adaptation process
of the body to the continuous challenge of infections and is the basis of the age-associated
decrease in immune competence that renders individuals more susceptible to diseases.
Immunosenescence is associated with an increase of morbidity and mortality [27, 35, 46]. One
of the typical aspects of immunosenescence is the profound modification within the cytokine
network leading to the development of a low-grade inflammatory status, known as “inflam‐
maging” [28]. This phenomenon is characterized by a general increase in plasmatic levels and
cell capability to produce pro-inflammatory cytokines (Interleukin-6, IL-6, Interleukin-1, IL-1
and Tumour Necrosis Factor-α, TNF-α) and by a subsequent increase of the main inflamma‐
tory markers, such as C-reactive protein (CRP) and serum amyloid A (A-SAA) [29, 31, 32]. This
generalized pro-inflammatory status, interacting with the genetic background and environ‐
mental factors, potentially triggers the onset of the most important age-related diseases, such
as cardiovascular diseases, atherosclerosis, metabolic syndrome, type 2 diabetes and obesity,
neurodegeneration, arthrosis and arthritis, osteoporosis and osteoarthritis, sarcopenia, major
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depression and frailty [46]. The first evidence of the age-associated modification in the balance
of cytokine network was described by [24] who found an increase of IL-6 plasma levels and a
corresponding decrease of IL-2 production in healthy elderly subjects [24, 26].
We have provided several contributions on the relevance of the inflammatory reaction at
the vascular site for cell senescence in terms of the reversibility of its inflammatory phe‐
notype [16,  17].  These data could be confirmed by ex vivo  data of Franceschi’s laborato‐
ry.  A  significant  increase  of  IL-6,  TNF-α  and  IL-1β  levels  were  described  in  mitogen-
stimulated cultures from aged donors.  Indeed,  cells  from aged people seem able to up-
regulate  the production of  these  cytokines  in  response to  appropriate  stimuli  indicating
that the cellular machinery for the production of these molecules remains active and effi‐
cient during aging [24]. It has been hypothesized that inflammaging could be due to the
antigenic  load  and  its  persistence  for  the  entire  lifespan.  Antigens  of  common  viruses
such as human cytomegalovirus (HCMV) or Epstein-Barr virus (EBV) represent a major
driving  force  for  the  activation  of  macrophages  and expansion  of  specific  T  cell  clones
(megaclones) producing a large amount of inflammatory cytokines [54, 55].  The increase
with  age  of  IL-6  plasma  levels  appears  to  be  unexpectedly  present  in  both  those  who
underwent  successful  aging and those  who suffered pathological  aging.  Thus,  we must
question  the  factors  responsible  for  successful  aging.  Data  obtained  on  centenarians  by
the Franceschi laboratory showed that centenarians also are inflamed [3, 4, 26]. Thus, in‐
flammaging per  se  is  not  incompatible  with longevity.  But  it  is  likely that  many protec‐
tive  factors,  such  as  the  genetic  background,  epigenetic  markers  [33]  and  anti-
inflammatory  molecules  can  play  a  pivotal  role  in  counteracting  unfavourable  pro-
inflammatory signalling [32].
At present it is not understood whether the alteration in the regulation of inflammatory reac‐
tions could be a cause or rather an effect (or both in a vicious cycle) of the aging process as a
whole. A wide range of elements has been claimed to contribute to the development of low-
grade inflammation. In particular, in addition to the main impact of the immune system, a vari‐
ety of tissues (adipose tissue and muscle in particular), organs (liver and brain) and ecosystems
(skin, mouth, vagina and gut microbiota) differently contribute to inflammaging onset, pro‐
gression and persistence having specific organ-restricted and/or systemic effects [13].
Gut microbiota and the gastrointestinal-associated immune system coexist in a balanced
microenvironment where cytokines and lymphocytes have to cope with the antigenic load, in
order to control the enormous variety of bacterial species within the intestinal microflora.
During aging, subtle changes in intestinal microbial structure may contribute to the age-related
inflammatory status. A reduction of some populations of Clostridia in favour of enrichment in
facultative anaerobes in centenarians has been described. In addition, the remodelling of
centenarians’ microbiota was associated with an increased inflammatory state, determined by
a series of peripheral inflammatory markers (IL-6, IL-8) [7]. The dysbiosis observed in these
extremely long-lived subjects represents an important source of continuous antigenic stimu‐
lation (immune/inflammatory/toxic/metabolic) to other organs and systems, such as the
immune system and the liver, contributing to the development and maintenance of inflam‐
maging. So why are healthy centenarians the best example of successful ageing, even if they
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are characterized by inflammaging? Our hypothesis is that their reduced capacity to mount
strong inflammatory responses is due to a remarkable genetic pattern (based on anti-inflam‐
matory gene variants) and is able to limit the inflammatory process. A protective genetic
component towards the development of age-related pathologies with a strong inflammatory
pathogenesis would thus be exerted [32].
Inflammaging can, in turn, undermine the balance between gut microbiota and the gastroin‐
testinal-associated immune system, contributing to the establishment of a vicious inflamma‐
tory cycle [8]. Importantly, recent literature suggests the impact of microbiota inflammatory
stimuli on the brain [6]. Several studies even suggest an inflammatory pathogenesis at the basis
of activation of microglia in response to injury, illness and aging, as described in the following
section.
2. Neuro-inflammation
The term neuro-inflammation designates chronic, CNS-specific, inflammation-like glial
responses that do not reproduce the classic characteristics of inflammation in the periphery
but that may provoke neuro-degenerative events, including plaque formation, dystrophic
neurite growth and unwarranted tau phosphorylation, among other signs. Aetiology of neuro-
inflammation is not yet clarified even if many strides forward have been made in this field. In
fact, during the last decades important discoveries have been made, particularly on risk factors,
genetic-associated variants, pro-inflammatory molecules, cellular and sub-cellular modified
processes and, ultimately, the gene expression pathways shared in many neuro-degenerative
diseases, such as AD. A recent review summarizes microarray human studies in neuro-
degenerative diseases showing gene expression profiles shared in these age-associated
diseases [15], highlighting the inflammatory component. In addition, RNA splicing and
protein turnover are found to be disrupted and mitochondrial dysfunction has been reported.
Franceschi’s team is heavily involved in the study of age-related diseases and in particu‐
lar AD, either in terms of nuclear and mitochondrial genetic variants and pro-inflammato‐
ry  environments  [21,  22,  36-39,  45,  49].  It  is  well  known  that  AD  is  a  fast  growing
worldwide pathology: it  is  a slowly progressive and, after early stage reversible phases,
irreversible  neuro-degenerative  disease.  Patients  undergo  decades  of  symptomatic  pro‐
gression; multiple interacting molecular mechanisms contribute to the development of the
early clinical prodromal stages characterized by episodic memory deficits and decline, as
well as impairment of general cognitive functioning, particularly during the final syndro‐
mal  dementia  stage (reviewed in [34]).  In the context  of  AD research,  the team studied
the  role  of  genetic  cytokines  variants,  such  as  IL-1,  IL-6,  TNF-α  and  interferon-gamma
(IFN-γ), in AD patients. The data showed the association between the plasmatic and brain
level of IL-6 and IL-6 polymorphisms at 174 position in the promoter region, suggesting a
relationship between specific gene variants and circulating levels of a specific inflammato‐
ry cytokine; furthermore, cytokine blood level mirrors the quantity of its level in the brain
[38].  Similarly, increased levels of IL-1, another pro-inflammatory cytokine, are observed
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in association with specific IL-1 gene variants [21]. We think that these findings can be in‐
tegrated into the more general vision of the inflammaging process, i.e. the chronic age-re‐
lated pro-inflammatory status together with unfavourable genetic variants can contribute
to neuro-inflammation pathogenesis and the onset of AD or neuro-degenerative diseases
[30, 11]. Many inflammatory mediators have been detected in regions of the brain of pa‐
tients with AD [45] according to the hypothesis that inflammation might contribute to the
neuro-degeneration characterizing this pathology [42].
The activation of the microglia may be due either to local and/or systemic inflammation. In
fact, a strong local inflammatory stimulus, such as a previous head trauma, is a risk factor for
AD onset and several epidemiological studies clearly show that blood elevations of acute phase
proteins, markers of systemic inflammatory stimuli, may be risk factors for cognitive decline
and dementia [21, 52]. Moreover, in AD, astrocytes are involved in the production of neurotoxic
substances, such as reactive oxygen and nitrogen species, pro-inflammatory cytokines,
complement proteins, and other inflammatory mediators that bring about important neuro-
degenerative changes [53].
However, the scenario is much more complex than previously thought. The Franceschi group
also identified key molecular actors, such as proteasome and immune-proteasome (the
molecular complex induced by INFs), as possible motors of protein turnover alteration [43].
The immune-proteasome has been associated with neuro-degenerative and autoimmune
diseases as a marker and regulator of inflammatory mechanisms. Its expression in the brain
may occur upon neuro-inflammation in different cell types and affect a variety of homeostatic
and inflammatory pathways including the oxidized protein clearance and the self-antigen
presentation. Recently, its role in epilepsy has been established. In fact the pathology-specific
pattern of immune-proteasome expression could provide insight into the complex neuro-
inflammatory pathogenic components of this disease [44]. The same group is currently
working on the circulating proteasome/immuneproteasome, in order to establish its role as a
possible early-biomarker in neuro-degenerative and inflammatory diseases. In this regard, the
circulating mitochondrial DNA, another systemic biomarker of inflammation and disease, is
also being investigated [57]. This type of research could be strategic for the improvement of
therapeutic intervention, one of the priorities of the current European and US research. The
possibility, as well as the difficulty, of identifying a pro-inflammatory prodromal phenotype
which will develop the syndromic stage, is crucial for the prevention, diagnosis and therapy
of AD and other age-related neuro-degenerative pathologies [56].
The study of post-operative delirium (POD) in elderly patients [1, 2] has been promoted by
the same approach. Recent literature suggests the presence of an inflammatory component in
the POD onset, showing again the close relationship between systemic inflammation and CNS,
particularly when a stressful event such as surgery (or anaesthesia) or infectious diseases may
provoke an acute exacerbation (delirium) interacting with pre-intra and post-operative
parameters. One of the main hypotheses related to the delirium onset is that peripherally
produced pro-inflammatory cytokines enter the brain and activate microglia. Activated
microglia may produce inflammatory mediators affecting neuronal functioning, that may be
implicated in the symptomatology of delirium.
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What are the physiological mechanisms to counteract the pro-inflammatory activation of
neuro-inflammation? One of the best characterized is the cholinergic inhibition that con‐
trols  microglia  activation  and  thereby  limits  the  severity  and  duration  of  delirium.  If
cholinergic  inhibition  fails,  either  because  of  pre-existing  neuro-degeneration  or  use  of
drugs with anticholinergic effects,  neuro-inflammation could spin out of control,  leading
to  severe  prolonged delirium that  can become associated with  dementia  [51].  Thus,  the
first  event,  i.e.,  POD,  is  often  a  prodromal  event  for  the  development  of  dementia  or
AD, i.e., a long-term cognitive decline and also an increased mortality. On this last point
limited literature  is  currently  available.  It  is  noteworthy that  the  inflammatory  markers
are already abundantly present before the post-operative delirium episode (in particular
IL-6,  IL-8  and CRP)  [5]  and sometimes this  pro-inflammatory status  is  accompanied by
the  decrease  of  anti-inflammatory  molecules  such  as  Acetylcholinesterase  enzyme
(AchE), inducing an imbalance between pro- and anti-inflammatory responses [12].
In progress data from the Franceschi laboratory suggest that the assessing of the level of
specific plasmatic pro-inflammatory cytokines, together with other parameters [2], before
surgery could be the best strategy for early identification of patients who could develop
POD and not only for the best management of patients on the ward. This could lead to
fast  tracking  of  elderly  patients  who  could  develop  neuro-degenerative  diseases  in  the
future.
Another model studied by the same laboratory is Down Syndrome (DS), a progeroid syndrome
characterized by an accelerated neuro-degenerative process [25, 40]. Ongoing analyses on a
cross sectional cohort by means of an ad hoc test battery for cognitive and functional assess‐
ments could be essential in gathering evidence on brain areas that first undergo neuro-
degeneration.
The strategy for counteracting these different age-related neuro-degenerative clinical pic‐
tures and diseases is of primary importance and represents one of most fascinating areas
in the field of aging and age-related disease research. In order to slow down and counter‐
act the “destiny” of early identified risk factors in an elderly patient candidate for surgi‐
cal  treatment,  what  could  be  the  most  eligible  non-invasive  and  non-toxic  therapeutic
intervention? Our driving hypothesis  is  that  we can restrain the onset  and the progres‐
sion of the age-related neuro-degenerative diseases counteracting immunosenescence [10]
and inflammaging by diet intervention, moderate and daily physical exercise and the pos‐
sible  use  of  natural  compounds,  whose formulation allows specifically  reducing inflam‐
matory markers in tissues, cells and blood.
3. Anti-inflammaging/anti-stress intervention
Chronic inflammation is an underlying cause of many apparently unrelated, age-related
diseases. This fact is often overlooked, yet persuasive scientific evidence exists that correcting
a chronic inflammatory disorder will enable many of the infirmities of aging to be prevented
or reversed. When we envisage a link between aging and recurrent or chronic inflammation,
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we refer to the pathological consequences of inflammation in well-documented medical
literature. Regrettably, the origins as well as the consequences of systemic inflammation
continue to be an unsolved problem. By following specific prevention protocols (such as
weight loss), the inflammatory stimulation could be significantly reduced. An important role
in preventing the onset of a chronic inflammatory condition has been attributed either to the
practice of a physical activity or to the prescription of a personalized diet, or both.
Terpens are a large and varied class of  organic components classified as secondary me‐
tabolites. They are produced by a wide variety of plants, particularly conifers, though al‐
so  by  some  insects,  such  as  swallowtail  butterflies,  which  emit  terpens  from  their
osmeterium.  They are  the  major  components  of  resin  and of  turpentine  produced from
resin.  The  name  terpen  is  derived  from  the  word  “turpentine”.  The  smaller  and  more
volatile  terpenoids  (C10  and  C15)  are  generally  the  main  constituents  of  the  essential
oils obtained from many types of plants and flowers, widely used as natural flavourings
for  food,  as  fragrances  in  perfumes  in  aromatherapy  and  in  traditional  and  alternative
medicines.  Terpenoids  possess  a  common  structural  feature:  they  contain  an  integral
number of C5 units (isoprene-like) giving a basic molecular formula (C5H8)n for the hy‐
drocarbons  series.  They  are  derived  from  the  metabolism  of  acetate  by  the  mevalonic
acid branch biosynthetic pathways of plants.
Examples of monoterpens (C10) are geraniol and limonene. In particular, d-limonene has a
pronounced chemotherapeutic activity and minimal toxicity in pre-clinical studies. A phase I
clinical trial performed to assess toxicity, maximum tolerated dose (MTD) and pharmacoki‐
netics in patients with advanced cancer was followed by a limited phase II evaluation in breast
cancer. We have previously published some in vitro results on a tri-terpen [58], implicating a
NF-κB dependent anti-inflammatory mechanism of action of the extract of Trytergium Wolfor‐
dii hoek, used in traditional Chinese medicine for the prevention of arthritis, rheumatoid
arthritis and arthrosis.
In performing the experiments for the assessment of the doses to be administered in an in
vivo rodent model, an anti-stress effect of the terpen AISA 5203-L was unexpectedly revealed
by a functional observation battery (FOB). A plethora of parameters addressing behavioural,
physiological and neurological parameters in female rats submitted to several stressful
conditions were measured. Results showed important effects leading to the capacity of the
animals to tolerate stress and even pain when compared to vehicle-treated animals [9].
To these preliminary pre-clinical data we were recently able to add some clinical data showing
the coherence of our anti-inflammatory/anti-stress approach [18, 19]. The European Capacity
study “Ristomed” enrolled 125 healthy individuals from three different countries (Italy, France
and Germany). They all received an ‘optimal diet for the elderly’ with the supplementation of
some nutraceutic compounds for a period of 56 days. The diet was developed on the basis of
the current recommendations for elderly people and personalized individual dietary require‐
ments, with particular attention given to food compounds that can affect inflammation,
oxidative stress and gut microbiota, such as polyunsaturated fatty acids (PUFAs), antioxidant
vitamins, polyphenols, flavonoids and fibres. The diet was adapted to the dietary habits for
each country. AISA Therapeutics treatment (here referred to as OPE, i.e., Orange Peel Extract)
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associated as dietary supplementation in addition to the Ristomed diet was validated as an
anti-inflammatory food complement.
In this article, we will report the results concerning the inflammatory markers and the
(concomitant) alterations of the mood, comparing the group receiving the diet without
supplementation (14 males, mean age 69.6 ± 4.1 years; 17 females, 71.3 ± 3.8 years) to that
receiving a diet supplemented with daily soft gel capsules containing the terpen extract AISA
5203-L (14 males, mean age 70.6 ± 4.4 years; 16 females, 69.6 ± 3.3 years), related to as OPE
(Orange Peel Extract).
The laboratory measurements  performed included erythrocyte  sedimentation rate  (ESR),
high-sensitivity  C-reactive  protein  (CRP),  white  blood  cell  count  (WBC)  and  fibrinogen
measurements.  Baseline  plasma  levels  of  ESR,  CRP,  WBC,  fibrinogen,  IL-6  and  TNF-α
were used to calculate an inflammation score. This enabled the separation of the patients
into two groups of respectively low and high inflammation, so that inflammatory status
could be evaluated according to the scores of these markers.
Moreover, several self-assessment questionnaires were analysed to investigate quality of life
parameters. The SF-36v2 Health Survey was used to evaluate what each subject felt about his/
her health using 36 items covering functional status, wellbeing and an overall evaluation of
health, that together are referred to as Quality of Life (QoL). Two summary scores — Physical
Component Summary (PCS) and Mental Component Summary (MCS) — were calculated to
distinguish a possible physical dysfunction and bodily pain from psychological distress and
emotional problems. The State-Trait Anxiety Inventory-X (STAI-X) questionnaire was used to
assess the anxiety state and trait, and to describe each subject’s feelings at a particular point.
The results of this investigation showed that among clinically healthy, aged subjects (i.e.,
absence of cancer, obesity, metabolic syndrome, diabetes, major cardiovascular complaints,
arthritis or dementia), a third of them showed important inflammatory markers’ expression.
It is precisely these patients that could be at risk of developing delirium in the case of surgical
treatment [2]. They would largely be advantaged by a preventive treatment of their inflam‐
matory condition, especially if high levels of IL-6 and TNF-α are measured.
Conclusively,  the results confirmed the anti-inflammatory action of the terpen extract in
an aged matched (65-85) healthy population (figure 1 and [20], www.ristomed.eu).
Moreover,  Ristomed results  were  conclusive  also  for  the  capacity  to  lower  anxiety  and
thus implicitly for the link between inflammation and anxiety. Interestingly, study results
obtained for quality of life assessment (PCS, MCS and GHQ-12), mood (STAI-X) and de‐
pression (CES-D) confirmed our findings on mood modulation. We note in particular that
OPE treatment was more effective in high-inflamed patients, the anti-depressive effect is
more visible in low-inflamed patients (figure 2). These results also confirm previous find‐
ings  established  by  our  Functional  Observation  Battery  (FOB)  in  rodents,  where  AISA
5203-L supplementation was able to substantially contribute to pain tolerance and mood
stabilization.  However,  the  most  intriguing  result  was  the  fact  that  the  stressed  animal
(non-pathological  stress  stimulating  anxiety),  instead  of  developing  a  freezing  attitude,
following oral administration of the food supplement,  developed an activity.  These data
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can be useful to answer the question “Is stress relevant for cell  senescence and thus ag‐
ing?”. The important effects on mood in the presence of stress situations has been docu‐
mented  for  decades.  The  mechanism  by  which  a  stress  is  responsible  for  detrimental
organ impairment seems to reside in the complex interconnections between inflammatory
and immunosenescence pathways [14, 23, 41, 50].
In conclusion, inflammaging is an age-related process arising from the interaction with the
genetic/epigenetic/microbioma–specific background and the environment, as shown in figure
3, and this interaction potentially triggers the onset of the most important age-related diseases.
In this regard, lessons from the clinical research teach us that inflammation as well as mood
alterations seem relevant for the onset of degenerative diseases. The balancing between pro-
and anti-inflammatory agents can be modified by external stimuli both in terms of stress or
Figure 1. Results of the Ristomed study: inflammation sub-groups and IL-6 variation in diet versus diet plus terpen
extract AISA 5203-L, in the figure mentioned as OPE (i.e., Orange Peel Extract).
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anti-stress effects. The evidence that post-surgery delirium episodes precipitating dementia
are announced by anxiety that in turn is associated to high inflammatory scores, allows us to
research efficacious presides to treat these cases. A preventive administration of non-toxic food
additives counteracting inflammation and soothing mood alterations could be integrated into
the daily diet preceding the surgical intervention. A preventive administration of highly anti-
inflammatory specific biocomplements should be included in the recommendations to the
healthy aged population by medical institutions and supported by healthy aging guidelines
in western countries.
Finally, in order to counteract inflammatory stimuli and to modulate the impact of the
environment on inflammaging, we proposed to intervene with diet and food supplementation.
Figure 2. Inflammation subgroups and CES-D variation in diet versus diet plus OPE.
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Figure 3. The Inflammaging balance. The low, chronic pro-inflammatory status, characterizing aging interacts with
genetic/epigenetic/microbiota background and potentially triggers the onset of the most important age-related dis‐
eases. The balancing between pro- and anti-inflammatory agents can be modified by external stimuli, such as stress or
anti-stress (diet and anti-inflammatory compounds). PG: prostaglandins; LT: leukotrienes, LPX: lipoxins
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